Pharmacokinetic/Pharmacodynamic Analysis of Neutrophil Proliferation Induced by rhG-CSF in Patients Receiving Antineoplastic Drugs

Access this Article

Search this Article

Author(s)

    • 杉浦 宗敏 SUGIURA Munetoshi
    • 東京大学医学部附属病院薬剤部 Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo
    • 大野 能之 OHNO Yoshiyuki
    • 東京大学医学部附属病院薬剤部 Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo
    • 鈴木 洋史 SUZUKI Hiroshi
    • 東京大学医学部附属病院薬剤部 Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo
    • 伊賀 立二 IGA Tatsuji
    • 東京大学医学部附属病院薬剤部 Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo

Abstract

  In the present study, we analyzed the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on neutrophil counts in cancer patients undergoing chemotherapy using a previously developed pharmacokinetic/pharmacodynamic model.<sup>7)</sup> The time profiles of neutrophil counts in blood after repeated administration of rhG-CSF to lung cancer patients undergoing chemotherapy could be analyzed by this model by considering the inhibition of neutrophil production by antineoplastic drugs. Although deviation was observed between the predicted and observed neutrophil counts in ovarian cancer patients, it may be possible to use this model for determining a rational dosage regimen of rhG-CSF for patients undergoing chemotherapy.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 124(9), 599-604, 2004-09-01

    The Pharmaceutical Society of Japan

References:  15

Codes

  • NII Article ID (NAID)
    110003614991
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    00316903
  • NDL Article ID
    7079355
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-411
  • Data Source
    CJP  NDL  NII-ELS  J-STAGE 
Page Top